https://www.onclive.com/view/retrospective-data-show-zanubrutinib-may-less-afib-burden-in-real-world-cll2026-06-03T19:41:35.522Z2026-06-03T19:41:35.522Z https://www.onclive.com/view/dato-dxd-hits-key-secondary-efficacy-end-points-in-first-line-tnbc2026-06-03T19:14:11.261Z2026-06-03T19:14:11.261Z https://www.onclive.com/view/ctdna-status-has-strong-prognostic-value-outperforming-pcr-status-in-early-tnbc2026-06-03T18:49:29.496Z2026-06-03T18:49:29.496Z https://www.onclive.com/view/the-power-of-patient-provider-dialogue-to-help-shape-first-line-treatment-for-ph-cml-in-chronic-phase2026-06-03T18:00:27.581Z2026-06-03T18:00:27.581Z https://www.onclive.com/view/uncertainties-surrounding-hpv-vaccination-may-hamper-the-full-potential-of-a-proven-cancer-prevention-strategy2026-06-03T16:55:28.609Z2026-06-03T16:55:28.609Z https://www.onclive.com/view/antibody-drug-conjugates-in-lung-cancer-the-tip-of-the-iceberg2026-06-03T16:00:00Z2026-06-03T16:00:00Z https://www.onclive.com/view/dr-galsky-on-the-evolution-of-the-muscle-invasive-bladder-cancer-treatment-landscape2026-06-03T14:10:55.893Z2026-06-03T14:10:55.893Z https://www.onclive.com/view/adjuvant-sintilimab-plus-capecitabine-fails-to-improve-pfs-over-capecitabine-alone-in-suboptimal-response-locoregionally-advanced-npc2026-06-03T13:25:00Z2026-06-03T13:25:00Z https://www.onclive.com/view/asco-ut-md-anderson-faculty-honored-as-2026-special-award-recipients2026-06-03T13:00:00Z2026-06-03T13:00:00Z https://www.onclive.com/view/esaona-data-support-asandeutertinib-as-a-frontline-option-in-egfr-nsclc-with-brain-metastases2026-06-03T12:00:00Z2026-06-03T12:00:00Z https://www.onclive.com/view/dr-soff-on-the-role-of-romiplostim-in-managing-cit-in-gi-cancers2026-06-03T12:00:00Z2026-06-03T12:00:00Z https://www.onclive.com/view/selinexor-plus-ruxolitinib-yields-superior-spleen-responses-os-signal-in-jak-inhibitor-na-ve-myelofibrosis2026-06-03T01:31:59.953Z2026-06-03T01:31:59.953Z https://www.onclive.com/view/dr-eads-on-early-data-for-cdh17-directed-car-t-cell-therapy-in-r-r-gi-cancers2026-06-02T23:16:34.124Z2026-06-02T23:16:34.124Z https://www.onclive.com/view/herizon-gea-01-pd-l1-subgroup-data-support-zanidatamab-combo-as-a-new-frontline-soc-in-her2-gea2026-06-02T23:06:09.132Z2026-06-02T23:06:09.132Z https://www.onclive.com/view/dr-mascarenhas-on-data-for-selinexor-plus-ruxolitinib-in-jak-inhibitor-naive-myelofibrosis2026-06-02T22:57:41.020Z2026-06-02T22:57:41.020Z https://www.onclive.com/view/talapro-3-talazoparib-enzalutamide-rpfs-hrr-altered-mcspc2026-06-02T22:44:02.669Z2026-06-02T22:44:02.669Z https://www.onclive.com/view/serena-6-meets-pfs2-end-point-with-early-switch-to-camizestrant-in-er-her2-negative-esr1-mutated-advanced-breast-cancer2026-06-02T22:05:00Z2026-06-02T22:05:00Z https://www.onclive.com/view/giredestrant-plus-palbociclib-yields-numerical-pfs-benefit-in-er-her2-advanced-breast-cancer2026-06-02T22:02:44.772Z2026-06-02T22:02:44.772Z https://www.onclive.com/view/dr-phillips-on-the-significance-of-the-fda-approval-of-sonrotoclax-for-r-r-mcl2026-06-02T20:32:47.683Z2026-06-02T20:32:47.683Z https://www.onclive.com/view/lutetium-lu-177-vipivotide-tetraxetan-triplet-shows-consistent-rpfs-benefit-across-disease-volume-and-mhspc-status-subgroups2026-06-02T19:01:45.277Z2026-06-02T19:01:45.277Z https://www.onclive.com/view/advancing-bladder-cancer-care-through-education-and-awareness2026-06-02T18:00:00Z2026-06-02T18:00:00Z https://www.onclive.com/view/sacituzumab-govitecan-plus-pembrolizumab-provides-pfs2-benefit-in-first-line-pd-l1-mtnbc2026-06-02T16:45:05.822Z2026-06-02T16:45:05.822Z https://www.onclive.com/view/fda-approves-orally-disintegrating-nilotinib-tablets-for-chronic-myeloid-leukemia2026-06-02T16:12:35.272Z2026-06-02T16:12:35.272Z https://www.onclive.com/view/first-line-pemigatinib-drives-pfs-benefit-in-fgfr2-rearranged-cholangiocarcinoma2026-06-02T14:58:57.001Z2026-06-02T14:58:57.001Z https://www.onclive.com/view/sacituzumab-govitecan-based-regimens-show-pfs-benefit-across-biomarker-subgroups-in-first-line-advanced-tnbc2026-06-02T14:23:25.381Z2026-06-02T14:23:25.381Z https://www.onclive.com/view/breast-cancer-drug-is-effective-for-treatment-resistant-uterine-cancer2026-06-02T14:01:09.114Z2026-06-02T14:01:09.114Z https://www.onclive.com/view/aligning-treatment-intensity-with-access-and-visit-burden2026-05-19T14:30:00.000Z2026-06-02T12:05:00Z https://www.onclive.com/view/current-adc-practice-in-cervical-cancer2026-06-02T12:05:00Z2026-06-02T12:05:00Z https://www.onclive.com/view/what-ovarian-adcs-still-need-to-deliver2026-06-02T12:00:00Z2026-06-02T12:00:00Z https://www.onclive.com/view/case-discussion-high-disease-burden-and-tp53-co-mutation2026-05-19T14:30:00.000Z2026-06-02T12:00:00Z https://www.onclive.com/view/neoadjuvant-rilvegostomig-plus-t-dxd-drives-drives-pcrs-in-immune-positive-her2-negative-breast-cancer2026-06-02T11:30:00Z2026-06-02T11:30:00Z https://www.onclive.com/view/atebimetinib-plus-modified-gemcitabine-nab-paclitaxel-shows-encouraging-efficacy-tolerability-in-first-line-metastatic-pdac2026-06-01T23:30:57.237Z2026-06-01T23:30:57.237Z https://www.onclive.com/view/darovasertib-plus-crizotinib-delivers-pfs-gains-in-hla-a2-negative-metastatic-uveal-melanoma2026-06-01T22:21:16.887Z2026-06-01T22:21:16.887Z https://www.onclive.com/view/dr-mileshkin-on-the-efficacy-of-puxi-sam-in-gynecologic-cancers2026-06-01T21:25:00Z2026-06-01T21:25:00Z https://www.onclive.com/view/dr-mok-on-the-long-term-efficacy-of-first-line-lorlatinib-in-advanced-alk-nsclc2026-06-01T21:15:22.215Z2026-06-01T21:15:22.215Z https://www.onclive.com/view/osimertinib-plus-chemotherapy-improves-pfs-in-ctdna-persistent-egfr-mutant-nsclc2026-06-01T20:24:38.991Z2026-06-01T20:24:38.991Z https://www.onclive.com/view/navigating-radiation-systemic-therapy-and-multidisciplinary-care-in-skin-cancer-with-hirsch-matani-md-elizabeth-zhang-velten-md-phd-and-binh-t-ngo-md2026-06-01T19:55:08.813Z2026-06-01T19:55:08.813Z https://www.onclive.com/view/durvalumab-plus-bcg-shows-no-os-detriment-in-bcg-naive-high-risk-nmibc-at-5-years2026-06-01T17:05:37.692Z2026-06-01T17:05:37.692Z https://www.onclive.com/view/velzatinib-shows-activity-across-treatment-lines-and-kit-mutation-profiles-in-advanced-gist2026-06-01T16:17:37.127Z2026-06-01T16:17:37.127Z https://www.onclive.com/view/survival-gains-confirmed-full-keynote-522-data-set-to-redefine-treatment-standards-in-early-stage-tnbc-at-asco-20262026-06-01T14:36:13.603Z2026-06-01T14:36:13.603Z https://www.onclive.com/view/emerald-3-meets-primary-pfs-end-point-with-stride-plus-lenvatinib-and-tace-in-unresectable-embolization-eligible-hcc2026-06-01T12:52:08.051Z2026-06-01T12:52:08.051Z https://www.onclive.com/view/second-line-regimen-selection-in-egfr-mutant-nsclc-after-first-line-intensification2026-06-01T12:05:00Z2026-06-01T12:05:00Z https://www.onclive.com/view/integrating-biomarker-targeted-therapies-in-the-evolving-metastatic-colorectal-cancer-landscape2026-06-01T12:05:00Z2026-06-01T12:05:00Z https://www.onclive.com/view/recurrent-progressive-plgg-sequencing-targeted-therapies-retreatment-and-the-role-of-radiation2026-06-01T12:05:00Z2026-06-01T12:05:00Z https://www.onclive.com/view/safety-tolerability-and-patient-counseling-in-combination-therapy2026-06-01T12:00:00Z2026-06-01T12:00:00Z https://www.onclive.com/view/from-discovery-to-patient-care-vitamin-d-analog-shuts-down-pancreatic-cancer-s-shield-in-clinical-trial2026-06-01T12:00:00Z2026-06-01T12:00:00Z https://www.onclive.com/view/side-effects-of-targeted-therapies-from-mek-inhibitor-rash-to-tovorafenib-growth-concerns2026-06-01T12:00:00Z2026-06-01T12:00:00Z https://www.onclive.com/view/safety-profile-dose-management-and-treatment-positioning-of-zanzalintinib-plus-atezolizumab2026-06-01T12:00:00Z2026-06-01T12:00:00Z https://www.onclive.com/view/harmoni-6-shows-os-benefit-with-ivonescimab-chemo-over-tislelizumab-chemo-in-first-line-squamous-nsclc2026-05-31T23:23:00Z2026-05-31T23:23:00Z https://www.onclive.com/view/proteus-data-support-perioperative-apalutamide-plus-adt-as-new-soc-in-high-risk-localized-prostate-cancer2026-05-31T22:52:00Z2026-05-31T22:52:00Z https://www.onclive.com/view/abemaciclib-produces-first-positive-phase-3-trial-result-in-dedifferentiated-liposarcoma2026-05-31T22:51:24.515Z2026-05-31T22:51:24.515Z https://www.onclive.com/view/dr-king-on-the-efficacy-of-daraxonrasib-in-previously-treated-mpdac-from-rasolute-3022026-05-31T22:25:00Z2026-05-31T22:25:00Z https://www.onclive.com/view/dr-barlin-on-the-efficacy-of-gotistobart-plus-pembrolizumab-in-platinum-resistant-ovarian-cancer2026-05-31T22:15:58.121Z2026-05-31T22:15:58.121Z https://www.onclive.com/view/giredestrant-everolimus-drives-pfs2-chemotherapy-free-survival-benefits-in-er-her2-advanced-breast-cancer2026-05-31T19:18:09.209Z2026-05-31T19:18:09.209Z https://www.onclive.com/view/ctdna-guided-adjuvant-chemotherapy-improves-dfs-reduces-disease-recurrence-in-stage-ii-colon-cancer2026-05-31T18:36:47.684Z2026-05-31T18:36:47.684Z https://www.onclive.com/view/cepheus-final-analysis-dvrd-sustains-efficacy-benefits-in-transplant-ineligible-newly-diagnosed-multiple-myeloma2026-05-31T16:30:00Z2026-05-31T16:30:00Z https://www.onclive.com/view/breakwater-cohort-3-data-support-folfiri-as-a-chemo-backbone-with-encorafenib-cetuximab-in-braf-v600e-mcrc2026-05-31T14:54:04.350Z2026-05-31T14:54:04.350Z https://www.onclive.com/view/frontmind-results-tafasitamab-based-combo-yields-significant-pfs-benefit-over-r-chop-in-frontline-high-risk-dlbcl2026-05-31T14:32:00Z2026-05-31T14:32:00Z https://www.onclive.com/view/updated-ev-302-data-reinforce-enfortumab-vedotin-combo-s-durability-in-urothelial-carcinoma-at-asco-20262026-05-31T14:10:00.691Z2026-05-31T14:10:04.149Z https://www.onclive.com/view/adjuvant-selpercatinib-significantly-improves-efs-in-early-stage-ret-fusion-positive-nsclc2026-05-31T13:16:40.473Z2026-05-31T13:16:40.473Z https://www.onclive.com/view/daraxonrasib-meets-all-primary-key-secondary-efficacy-end-points-in-pretreated-pdac2026-05-31T12:43:43.835Z2026-05-31T12:43:43.835Z https://www.onclive.com/view/tmc-i-improves-os-over-paclitaxel-carboplatin-in-platinum-sensitive-recurrent-metastatic-hnscc2026-05-31T12:00:00Z2026-05-31T12:00:00Z https://www.onclive.com/view/dr-ho-on-the-efficacy-of-oz-v-in-p16-oropharyngeal-squamous-cell-carcinoma2026-05-31T10:14:00Z2026-05-31T10:14:00Z https://www.onclive.com/view/dr-gilbert-on-os-according-to-prior-taxane-use-in-proc-from-the-rosella-trial2026-05-30T22:30:00Z2026-05-30T22:30:00Z https://www.onclive.com/view/dr-olazagasti-on-career-fulfillment-and-intent-to-leave-among-oncology-physicians2026-05-30T22:25:00Z2026-05-30T22:25:00Z https://www.onclive.com/view/giredestrant-cuts-recurrence-risk-across-menopausal-status-in-er-her2--early-breast-cancer2026-05-30T22:07:22.148Z2026-05-30T22:07:22.148Z https://www.onclive.com/view/bezuclastinib-plus-sunitinib-cuts-risk-of-progression-or-death-in-half-vs-sunitinib-alone-in-advanced-gist2026-05-30T21:47:40.759Z2026-05-30T21:47:40.759Z https://www.onclive.com/view/puxitatug-samrotecan-elicits-high-response-rate-in-select-endometrial-cancers2026-05-30T21:14:12.480Z2026-05-30T21:14:12.480Z https://www.onclive.com/view/newer-agents-hope-to-raise-the-bar-in-alk--and-ret-positive-nsclc2026-05-30T20:21:49.843Z2026-05-30T20:21:49.843Z https://www.onclive.com/view/ibcfs-with-prosigna-guided-adjuvant-therapy-is-noninferior-to-chemoendocrine-therapy-in-er-her2-early-breast-cancer2026-05-30T20:05:47.601Z2026-05-30T20:05:47.601Z https://www.onclive.com/view/nectin-4-adc-ly4052031-yields-33-orr-after-enfortumab-vedotin-in-urothelial-cancer2026-05-30T19:46:55.156Z2026-05-30T19:46:55.156Z https://www.onclive.com/view/adjuvant-durvalumab-plus-tremelimumab-shows-dfs-advantage-over-active-monitoring-in-resected-rcc2026-05-30T18:57:05.820Z2026-05-30T18:57:05.820Z https://www.onclive.com/view/mezigodomide-based-regimen-delivers-significant-survival-benefits-in-r-r-multiple-myeloma2026-05-30T15:50:00Z2026-05-30T15:50:00Z https://www.onclive.com/view/dr-mccann-on-future-needs-in-breast-cancer-drug-development2026-05-30T10:46:00Z2026-05-30T10:46:00Z https://www.onclive.com/view/dr-mccann-on-the-use-of-first-line-trop2-directed-adcs-in-metastatic-tnbc2026-05-30T10:41:00Z2026-05-30T10:41:00Z https://www.onclive.com/view/dr-mccann-on-sequential-adc-use-in-her2-metastatic-breast-cancer2026-05-30T10:30:00Z2026-05-30T10:30:00Z https://www.onclive.com/view/dr-mccann-on-the-expanding-role-of-t-dxd-in-her2-breast-cancer-management2026-05-30T10:21:00Z2026-05-30T10:21:00Z https://www.onclive.com/view/litt-boosts-immunotherapy-efficacy-in-high-grade-astrocytoma2026-05-30T01:45:00Z2026-05-30T01:45:00Z https://www.onclive.com/view/relacorilant-nab-paclitaxel-maintains-os-benefit-irrespetive-of-prior-taxane-use-in-platinum-resistant-ovarian-cancer2026-05-30T01:24:14.266Z2026-05-30T01:24:14.266Z https://www.onclive.com/view/teclistamab-monotherapy-tops-soc-in-myeloma-with-phase-3-data-to-be-presented-at-asco-20262026-05-30T00:40:35.432Z2026-05-30T00:40:25.966Z https://www.onclive.com/view/sunvozertinib-shows-superior-efficacy-vs-chemo-in-frontline-advanced-egfr-exon-20-nsclc2026-05-30T00:18:37.116Z2026-05-30T00:18:37.116Z https://www.onclive.com/view/pembrolizumab-plus-chemotherapy-shows-long-term-os-benefit-in-advanced-recurrent-endometrial-cancer2026-05-29T20:20:53.523Z2026-05-29T23:40:53.862Z https://www.onclive.com/view/dreamm-9-final-analysis-yields-high-response-rates-in-transplant-ineligible-newly-diagnosed-multiple-myeloma2026-05-29T23:29:54.438Z2026-05-29T23:29:54.438Z https://www.onclive.com/view/chiauranib-plus-paclitaxel-displays-pfs-benefit-in-platinum-resistant-ovarian-cancer2026-05-29T23:13:43.589Z2026-05-29T23:13:43.589Z https://www.onclive.com/view/optitrop-lung05-shows-pfs-benefit-with-first-line-sac-tmt-plus-pembrolizumab-in-pd-l1-nsclc2026-05-29T22:30:21.244Z2026-05-29T22:30:21.244Z https://www.onclive.com/view/amivantamab-plus-lazertinib-produces-clinically-meaningful-os-in-atypical-egfr-mutated-advanced-nsclc2026-05-29T22:24:39.223Z2026-05-29T22:24:39.223Z https://www.onclive.com/view/dostarlimab-combo-shows-durable-disease-control-in-dmmr-msi-h-endometrial-cancer-full-data-due-at-asco-20262026-05-29T20:20:53.523Z2026-05-29T20:20:51.357Z https://www.onclive.com/view/seven-years-strong-updated-crown-data-to-showcase-lorlatinib-s-durability-in-alk-nsclc-at-asco-20262026-05-29T19:30:00.000Z2026-05-29T19:50:56.540Z https://www.onclive.com/view/third-bla-submission-planned-for-rp1-plus-nivolumab-in-advanced-melanoma-after-fda-alignment2026-05-29T15:29:57.884Z2026-05-29T15:29:57.884Z https://www.onclive.com/view/onclive-weekly-news-quiz-5-29-2026-test-your-knowledge-on-updates-in-nmibc-bpdcn-and-nsclc2026-05-29T14:44:22.962Z2026-05-29T14:44:22.962Z https://www.onclive.com/view/dr-fakih-on-the-rational-application-of-repeat-ctdna-testing-in-crc2026-05-29T14:00:00Z2026-05-29T14:00:00Z https://www.onclive.com/view/chemo-selection-in-metastatic-pancreatic-cancer-continues-to-evolve-with-kras-targeted-therapies-on-the-horizon2026-05-29T12:00:00Z2026-05-29T12:00:00Z https://www.onclive.com/view/rethinking-the-next-line-in-relapsed-refractory-multiple-myeloma-why-using-car-t-cell-therapy-earlier-matters2026-05-29T12:00:00Z2026-05-29T12:00:00Z https://www.onclive.com/view/a-subcutaneous-option-reshaping-egfr-mutated-nsclc-care2026-05-29T04:08:00Z2026-05-29T04:08:00Z https://www.onclive.com/view/the-moonlight-shift-dr-maurie-markman-on-oncology-s-hardest-problems2026-05-29T00:29:49.827Z2026-05-29T00:29:49.827Z https://www.onclive.com/view/b7-h3-adcs-show-promise-across-lung-prostate-and-gynecologic-cancers2026-05-28T21:31:29.061Z2026-05-28T21:31:29.061Z https://www.onclive.com/view/dr-ho-on-the-unique-mechanism-and-therapeutic-potential-of-oz-v-in-hnscc2026-05-28T21:26:34.830Z2026-05-28T21:26:34.830Z https://www.onclive.com/view/novel-technologies-augment-the-evolution-of-minimally-invasive-brain-tumor-surgery2026-05-28T20:15:00Z2026-05-28T20:15:00Z https://www.onclive.com/view/in-house-molecular-testing-in-nsclc-improves-turnaround-time-tissue-stewardship-and-multidisciplinary-coordination-featuring-anthony-chi-md-monica-peravali-md-and-archana-jadhav-md2026-05-28T20:10:00Z2026-05-28T20:10:00Z https://www.onclive.com/view/dr-ho-on-the-safety-profile-of-ozuriftamab-vedotin-in-hpv-associated-opscc2026-05-28T18:58:29.450Z2026-05-28T18:58:29.450Z